SpaceOAR System RWS in China

Boston Scientific Corporation15 enrolled

Overview

This study aims to evaluate the safety and performance of SpaceOAR System when it is used to create space between the rectum and prostate in men undergoing radiotherapy for localized T1-T2 prostate cancer in China via collecting the real word data of SpaceOAR System used, to generate local clinical evidence on Chinese patients.

This study is a retrospective and prospective, single arm, real world study. For those patients who have already received the SpaceOAR treatment before study kick-off, the data at baseline and the day of procedure will be retrospectively collected. For those patients who will receive SpaceOAR treatment after study kick-off, the clinical data at baseline, the day of procedure and 30 days post procedure will be prospectively collected. Up to 20 subjects with a pathologically confirmed diagnosis of clinical stage T1 or T2 prostate cancer indicated for radiotherapy will be enrolled, for there are chances of missing data in the real world study. A sample of 14 subjects provides at least 90% power for the primary objective.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Localized T1-T2 Prostate Cancer

Interventions

SpaceOAR TreatmentDEVICE

SpaceOAR System is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space it is the intent of SpaceOAR System to reduce the radiation dose delivered to the anterior rectum. The SpaceOAR System is composed of biodegradable material and maintains space for the entire course of prostate radiotherapy treatment and is completely absorbed by the patient's body over time.

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects has provided the written informed consent, willing to participate in clinical data collection and willing to receive visit at 30 days post procedure. (for subjects enrolled prospectively) * Subjects must have been pathologically confirmed prostate cancer with clinical stage T1-T2, and have been treated or will be treated with Space OAR Hydrogel in hospital in Hainan Boao Lecheng medical pilot zone. Exclusion Criteria- no specific exclusion criteria unless the patients refuse to sign the informed consent.

Locations (1)

Boao First Life Care Center-Hospital

Qionghai, Hainan, China

Outcomes

Primary Outcomes

Primary Effectiveness Endpoint

The distance between the posterior prostatic capsule and anterior rectal wall,

Time frame: Within 10 days post spaceOAR hydrogel administration.

Primary Safety Endpoint

Subjects with AEs related to SpaceOAR system and/or procedure within 30 days following procedure will be observed.

Time frame: Within 30 days following procedure

Secondary Outcomes

Functional Success

Distance Posterior Prostatic Capsule and Anterior Rectal Wall

Time frame: Within 10 days post spaceOAR hydrogel administration.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.